Hemofarm Celebrates 20 Years of Work of the Banja Luka Pharmaceutical Factory

Hemofarm company, pharmaceutical leader in BiH and this region, marked the 20th anniversary of founding the pharmaceutical solid dosage forms factory in Banjaluka.

Modern facilities of Hemofarm Banjaluka are in compliance with the top international pharmaceutical standards accompanied with highly professional personnel. A record year in production of solid dosage forms is behind Hemofarm, and the output of these facilities in 2022 reached 1,707 billion tablets.

“Hemofarm has been breaking its own records and another record year has just passed. We are part of the unique STADA group, which strongly steps forward into the field of innovation in all segments of pharmaceutical development, and precisely the investments, as well as the expansion of the portfolio with modern therapies, demonstrate its determination to invest in this region. In the last five years alone, more than 20 million euros have been invested in the plants of the Banja Luka factory, and that number shows the Group's clear commitment to invest in Hemofarm”, said Ronald Seeliger, CEO of Hemofarm.

Saša Urošević, director of Hemofarm in B&H, pointed out that Hemofarm had invested for decades, both in the employee development through ongoing education and professional training, and in the production and portfolio development.

“Our portfolio in B&H comprises more than 370 products in different forms and dosages. Year after year, we have been improving it by adding contemporary generations of products to the satisfaction of our customers who are offered an ever increasing selection of good quality and affordable medicines. The consumers are also our starting point when it comes to production. We have been increasing its volume and maintaining the highest level of product quality confirmed by our compliance with the demanding European and global regulations, as well as the best practice in our industry. These are the very reasons why the well-known brands Grippostad and Coldrex will be packed in the plants in Banjaluka. Through all segments of our work, we are devoted to caring for people's health as a trusted partner”, stated Urošević.

The pharmaceutical factory in Banjaluka was opened in 2003, while in August 2006 Hemofarm became a part of the German STADA Group, one of the largest global generic companies. This company produces a significant number of products intended for sales in the EU countries, which is a confirmation of its modern concept, state-of-the-art technological equipment and competence of its employees.

Taken over from: www.hemofarm.ba